Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Peripheral vision

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    43 result(s) found for: Peripheral vision. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-000848-14 Sponsor Protocol Number: 38RC12.228 Start Date*: 2014-07-23
    Sponsor Name:Centre Hospitalier Universitaire de Grenoble
    Full Title: Endothelin and Ischemic optic Neuropathy study group
    Medical condition: Endothelin and Ischemic Optic Neuropathy study group
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002569-20 Sponsor Protocol Number: BIELEFELD-Janssen-PHRCN-2017 Start Date*: 2018-11-06
    Sponsor Name:CHU Dijon Bourgogne
    Full Title: A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of ustekinumab in association with prednisone, for the treatment of non-infectious severe uveitis (NISU)
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002255-37 Sponsor Protocol Number: MGT-RPGR-022 Start Date*: 2022-05-26
    Sponsor Name:MeiraGTx UK II Limited
    Full Title: Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene
    Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) NL (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) DK (Trial now transitioned) DE (Prematurely Ended) IT (Trial now transitioned) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2020-002873-88 Sponsor Protocol Number: MGT-RPGR-021 Start Date*: 2022-07-19
    Sponsor Name:MeiraGTx UK II Limited
    Full Title: Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene
    Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed) NL (Ongoing) BE (Completed) ES (Ongoing) FR (Completed) DK (Completed) DE (Prematurely Ended) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-002729-74 Sponsor Protocol Number: PQ-421a-003 Start Date*: Information not available in EudraCT
    Sponsor Name:ProQR Therapeutics IV B.V.
    Full Title: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of t...
    Medical condition: Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NO (Completed) DK (Completed) NL (Ongoing) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004214-42 Sponsor Protocol Number: RETIRD02 Start Date*: 2012-09-03
    Sponsor Name:QLT Inc.
    Full Title: An Open-Label Study to Evaluate the Effects of Repeated Treatments of Oral QLT091001 on Safety and Vision Outcome in Subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due ...
    Medical condition: Leber Congenital Amaurosis Retinitis pigmentosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070667 Leber's congenital amaurosis PT
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000130-18 Sponsor Protocol Number: 1 Start Date*: 2020-10-09
    Sponsor Name:Fundación para la Inv. Biomédica Hospital Clínico San Carlos
    Full Title: Co-THEIA (Combination THerapy with mEthotrexate and adalImumAb for uveitis): Efficacy, safety and cost-effectiveness of methotrexate, adalimumab, or their combination in non infectious non anterior...
    Medical condition: Non infectious non anterior uveitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001383-18 Sponsor Protocol Number: Start Date*: 2015-11-30
    Sponsor Name:University of Oxford
    Full Title: An open label Phase 2 clinical trial of retinal gene therapy for choroideremia using an adeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1)
    Medical condition: Choroideremia - a currently incurable retinal degeneration caused by null mutations in the CHM gene encoding REP1 protein located on the X chromosome. The condition causes blindness in males by the...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10008791 Choroideremia LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-002204-27 Sponsor Protocol Number: GS030_CLIN_001 Start Date*: 2017-12-22
    Sponsor Name:GENSIGHT-BIOLOGICS
    Full Title: A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects with Retinitis Pigmentosa
    Medical condition: Retinitis Pigmentosa
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001053-44 Sponsor Protocol Number: Carotis-Rivaroxaban_CEUS_001 Start Date*: 2020-09-30
    Sponsor Name:Rigshospitalet, Department of Vascular Surgery
    Full Title: Stabilization of vulnerable atherosclerotic carotid plaques by Rivaroxaban as evaluated by 3D contrast enhanced ultrasound (CEUS)
    Medical condition: Patients with - Stable peripheral artery disease and - Asymptomatic, atherosclerotic plaque/stenosis in the carotid artery; asymptomatic regarding cerebral ischaemia including stroke and transient...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10075495 Internal carotid artery atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000425-31 Sponsor Protocol Number: MGT010 Start Date*: 2018-08-30
    Sponsor Name:MeiraGTx UK II Ltd
    Full Title: Long term follow-up study of participants following an open label, multicentre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/5-hRKp.RPGR) for gene therapy o...
    Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2005-002744-25 Sponsor Protocol Number: RK100.1 Start Date*: 2006-06-29
    Sponsor Name:Roskamp Institute
    Full Title: An open label evaluation of the safety and efficacy of nilvadipine in mild to moderate Alzheimer's Disease
    Medical condition: Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002728-19 Sponsor Protocol Number: PQ-421a-004 Start Date*: Information not available in EudraCT
    Sponsor Name:ProQR Therapeutics IV B.V.
    Full Title: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of t...
    Medical condition: Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NO (Prematurely Ended) DK (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003243-37 Sponsor Protocol Number: Start Date*: 2017-11-02
    Sponsor Name:MUST Coordinating Centre, John Hopkins Bloomberg School of Public Health
    Full Title: Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial
    Medical condition: Uveitic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10002709 Anterior uveitis LLT
    22.1 10015919 - Eye disorders 10022557 Intermediate uveitis LLT
    20.1 100000004862 10036370 Posterior uveitis LLT
    20.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    20.1 10015919 - Eye disorders 10058202 Cystoid macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2016-002523-28 Sponsor Protocol Number: KHAK1001 Start Date*: 2016-09-16
    Sponsor Name:Moorfields Eye Hospital
    Full Title: A Pilot Study Evaluating the Effect of Intravitreal Fluocinolone Acetonide (0.19mg) in Patients with Retinitis Pigmentosa
    Medical condition: Retinitis Pigmetosa.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003272-12 Sponsor Protocol Number: SIVS1012 Start Date*: 2014-04-08
    Sponsor Name:Moorfields Eye Hospital
    Full Title: Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy
    Medical condition: Proliferative Diabetic Retinopathy (PDR)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000304-29 Sponsor Protocol Number: Start Date*: 2016-04-05
    Sponsor Name:MUST Coordinating Centre, John Hopkins Bloomberg School of Public Health
    Full Title: Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial
    Medical condition: Uveitic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014995 10002709 Anterior uveitis LLT
    20.0 100000161411 10022557 Intermediate uveitis LLT
    20.0 100000014975 10033687 Panuveitis LLT
    20.0 100000015065 10036370 Posterior uveitis LLT
    20.0 10015919 - Eye disorders 10058202 Cystoid macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003770-32 Sponsor Protocol Number: CLR_14_05 Start Date*: 2016-01-04
    Sponsor Name:Sun Pharma Advanced Research Company
    Full Title: A Randomized, Double-Blind, Four Treatment, Four period, Crossover Study, with Placebo, Tizanidine Immediate Release and Diphenhydramine to Study the Effect of Tizanidine Extended Release on Simula...
    Medical condition: healthy volunteers (acute musculoskeletal pain)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000640-21 Sponsor Protocol Number: KetCRPS-2 Start Date*: 2021-11-10
    Sponsor Name:Center for Pain Medicine, Erasmus MC
    Full Title: Long-term pain modulation by intravenous esketamine in Complex Regional Pain Syndrome: a non-inferiority study
    Medical condition: Complex Regional Pain Syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000385-22 Sponsor Protocol Number: RF-2010-2318561 Start Date*: 2014-10-07
    Sponsor Name:Ospedale San Raffaele di Milano
    Full Title: Nerve Growth Factor eye drops as a novel treatment for vision loss in patients with Retinitis Pigmentosa: from preclinical to clinical Phase II trial.
    Medical condition: Retinitis pigmentosa with cystoid macular edema
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004853 10054467 Macular edema LLT
    17.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 19:19:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA